Real-world evaluation of compliance and preference in Alzheimer’s disease treatment

Ming-Chyi Pai, Hany Aref, Nazem Bassil, Nagaendran Kandiah, Jae Hong Lee, A. V. Srinivasan, Shelley diTommaso, Ozgur Yuksel

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Purpose: Rivastigmine transdermal patch has shown higher caregiver satisfaction and greater preference than oral formulation in patients with Alzheimer’s disease. However, there is limited literature available related to caregiver preference or treatment compliance in real-world clinical settings. To date, no such data are available from Asia and the Middle East, which account for a sizeable proportion of patients with Alzheimer’s disease. The objective of this study was to evaluate treatment preference and compliance with oral and transdermal medications in daily clinical practice in an ethnically diverse patient population from Asia and the Middle East with mild-to-moderate Alzheimer’s disease. Patients and methods: RECAP (Real-world Evaluation of Compliance And Preference in the treatment of Alzheimer’s disease) was a 24-week, multicenter, prospective, noninterventional study. Two treatment cohorts were observed during the study: oral (cholinesterase inhibitors or memantine) and transdermal (rivastigmine patch). Caregiver preference, physician preference, and patient compliance were evaluated at week 24. Results: A total of 978 of 1,931 enrolled patients (mean age: 72.8 years; 50.5% female) were in the transdermal cohort. For patients with exposure to both oral and transdermal monotherapy (n=330), a significant caregivers’ preference for the transdermal monotherapy was observed (82.7%; P<0.0001). Of the 89 participating physicians, 71 indicated preference for transder- mal monotherapy. Patient compliance was also significantly higher for transdermal than oral monotherapy (P<0.0001). Conclusion: Our study showed higher caregiver and physician preference and greater patient compliance with transdermal monotherapy in daily practice.

Original languageEnglish
Pages (from-to)1779-1788
Number of pages10
JournalClinical Interventions in Aging
Volume10
DOIs
Publication statusPublished - 2015 Nov 3

Fingerprint

Compliance
Alzheimer Disease
Rivastigmine
Caregivers
Patient Compliance
Transdermal Patch
Middle East
Physicians
Therapeutics
Memantine
Cholinesterase Inhibitors
Prospective Studies
Population

All Science Journal Classification (ASJC) codes

  • Geriatrics and Gerontology

Cite this

Pai, M-C., Aref, H., Bassil, N., Kandiah, N., Lee, J. H., Srinivasan, A. V., ... Yuksel, O. (2015). Real-world evaluation of compliance and preference in Alzheimer’s disease treatment. Clinical Interventions in Aging, 10, 1779-1788. https://doi.org/10.2147/CIA.S85319
Pai, Ming-Chyi ; Aref, Hany ; Bassil, Nazem ; Kandiah, Nagaendran ; Lee, Jae Hong ; Srinivasan, A. V. ; diTommaso, Shelley ; Yuksel, Ozgur. / Real-world evaluation of compliance and preference in Alzheimer’s disease treatment. In: Clinical Interventions in Aging. 2015 ; Vol. 10. pp. 1779-1788.
@article{dce75e3728bc49309a938a36c8cbc0dc,
title = "Real-world evaluation of compliance and preference in Alzheimer’s disease treatment",
abstract = "Purpose: Rivastigmine transdermal patch has shown higher caregiver satisfaction and greater preference than oral formulation in patients with Alzheimer’s disease. However, there is limited literature available related to caregiver preference or treatment compliance in real-world clinical settings. To date, no such data are available from Asia and the Middle East, which account for a sizeable proportion of patients with Alzheimer’s disease. The objective of this study was to evaluate treatment preference and compliance with oral and transdermal medications in daily clinical practice in an ethnically diverse patient population from Asia and the Middle East with mild-to-moderate Alzheimer’s disease. Patients and methods: RECAP (Real-world Evaluation of Compliance And Preference in the treatment of Alzheimer’s disease) was a 24-week, multicenter, prospective, noninterventional study. Two treatment cohorts were observed during the study: oral (cholinesterase inhibitors or memantine) and transdermal (rivastigmine patch). Caregiver preference, physician preference, and patient compliance were evaluated at week 24. Results: A total of 978 of 1,931 enrolled patients (mean age: 72.8 years; 50.5{\%} female) were in the transdermal cohort. For patients with exposure to both oral and transdermal monotherapy (n=330), a significant caregivers’ preference for the transdermal monotherapy was observed (82.7{\%}; P<0.0001). Of the 89 participating physicians, 71 indicated preference for transder- mal monotherapy. Patient compliance was also significantly higher for transdermal than oral monotherapy (P<0.0001). Conclusion: Our study showed higher caregiver and physician preference and greater patient compliance with transdermal monotherapy in daily practice.",
author = "Ming-Chyi Pai and Hany Aref and Nazem Bassil and Nagaendran Kandiah and Lee, {Jae Hong} and Srinivasan, {A. V.} and Shelley diTommaso and Ozgur Yuksel",
year = "2015",
month = "11",
day = "3",
doi = "10.2147/CIA.S85319",
language = "English",
volume = "10",
pages = "1779--1788",
journal = "Clinical Interventions in Aging",
issn = "1176-9092",
publisher = "Dove Medical Press Ltd.",

}

Pai, M-C, Aref, H, Bassil, N, Kandiah, N, Lee, JH, Srinivasan, AV, diTommaso, S & Yuksel, O 2015, 'Real-world evaluation of compliance and preference in Alzheimer’s disease treatment', Clinical Interventions in Aging, vol. 10, pp. 1779-1788. https://doi.org/10.2147/CIA.S85319

Real-world evaluation of compliance and preference in Alzheimer’s disease treatment. / Pai, Ming-Chyi; Aref, Hany; Bassil, Nazem; Kandiah, Nagaendran; Lee, Jae Hong; Srinivasan, A. V.; diTommaso, Shelley; Yuksel, Ozgur.

In: Clinical Interventions in Aging, Vol. 10, 03.11.2015, p. 1779-1788.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Real-world evaluation of compliance and preference in Alzheimer’s disease treatment

AU - Pai, Ming-Chyi

AU - Aref, Hany

AU - Bassil, Nazem

AU - Kandiah, Nagaendran

AU - Lee, Jae Hong

AU - Srinivasan, A. V.

AU - diTommaso, Shelley

AU - Yuksel, Ozgur

PY - 2015/11/3

Y1 - 2015/11/3

N2 - Purpose: Rivastigmine transdermal patch has shown higher caregiver satisfaction and greater preference than oral formulation in patients with Alzheimer’s disease. However, there is limited literature available related to caregiver preference or treatment compliance in real-world clinical settings. To date, no such data are available from Asia and the Middle East, which account for a sizeable proportion of patients with Alzheimer’s disease. The objective of this study was to evaluate treatment preference and compliance with oral and transdermal medications in daily clinical practice in an ethnically diverse patient population from Asia and the Middle East with mild-to-moderate Alzheimer’s disease. Patients and methods: RECAP (Real-world Evaluation of Compliance And Preference in the treatment of Alzheimer’s disease) was a 24-week, multicenter, prospective, noninterventional study. Two treatment cohorts were observed during the study: oral (cholinesterase inhibitors or memantine) and transdermal (rivastigmine patch). Caregiver preference, physician preference, and patient compliance were evaluated at week 24. Results: A total of 978 of 1,931 enrolled patients (mean age: 72.8 years; 50.5% female) were in the transdermal cohort. For patients with exposure to both oral and transdermal monotherapy (n=330), a significant caregivers’ preference for the transdermal monotherapy was observed (82.7%; P<0.0001). Of the 89 participating physicians, 71 indicated preference for transder- mal monotherapy. Patient compliance was also significantly higher for transdermal than oral monotherapy (P<0.0001). Conclusion: Our study showed higher caregiver and physician preference and greater patient compliance with transdermal monotherapy in daily practice.

AB - Purpose: Rivastigmine transdermal patch has shown higher caregiver satisfaction and greater preference than oral formulation in patients with Alzheimer’s disease. However, there is limited literature available related to caregiver preference or treatment compliance in real-world clinical settings. To date, no such data are available from Asia and the Middle East, which account for a sizeable proportion of patients with Alzheimer’s disease. The objective of this study was to evaluate treatment preference and compliance with oral and transdermal medications in daily clinical practice in an ethnically diverse patient population from Asia and the Middle East with mild-to-moderate Alzheimer’s disease. Patients and methods: RECAP (Real-world Evaluation of Compliance And Preference in the treatment of Alzheimer’s disease) was a 24-week, multicenter, prospective, noninterventional study. Two treatment cohorts were observed during the study: oral (cholinesterase inhibitors or memantine) and transdermal (rivastigmine patch). Caregiver preference, physician preference, and patient compliance were evaluated at week 24. Results: A total of 978 of 1,931 enrolled patients (mean age: 72.8 years; 50.5% female) were in the transdermal cohort. For patients with exposure to both oral and transdermal monotherapy (n=330), a significant caregivers’ preference for the transdermal monotherapy was observed (82.7%; P<0.0001). Of the 89 participating physicians, 71 indicated preference for transder- mal monotherapy. Patient compliance was also significantly higher for transdermal than oral monotherapy (P<0.0001). Conclusion: Our study showed higher caregiver and physician preference and greater patient compliance with transdermal monotherapy in daily practice.

UR - http://www.scopus.com/inward/record.url?scp=84946575131&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946575131&partnerID=8YFLogxK

U2 - 10.2147/CIA.S85319

DO - 10.2147/CIA.S85319

M3 - Article

C2 - 26622172

AN - SCOPUS:84946575131

VL - 10

SP - 1779

EP - 1788

JO - Clinical Interventions in Aging

JF - Clinical Interventions in Aging

SN - 1176-9092

ER -